Skip to main content

Goldman Says Narrow Breadth in S&P 500 a Bad Sign for Stocks

Goldman Says Narrow Breadth in S&P 500 a Bad Sign for Stocks(Bloomberg) -- The narrowing group of winners in the S&P 500 doesn’t bode well for the future performance of U.S. stocks, according to Goldman Sachs Group Inc.The U.S. benchmark is around 17% below its February record, but the median stock trades 28% from its peak, Goldman strategists including David Kostin wrote in a note Friday. Meanwhile, the five largest companies make up 20% of the gauge’s market capitalization, exceeding the 18% level the measure reached in March 2000 and raising investor concerns about narrow market breadth, they said.“Sharp declines in market breadth in the past have often signaled large market drawdowns,” the strategists wrote. “Narrow breadth can last for extended periods, but past episodes have signaled below-average market returns and eventual momentum reversals.”Breadth narrowed ahead of the recessions in 1990 and 2008, in the tech bubble, and during the economic slowdowns of 2011 and 2016, according to the note. In the recent rally, market leaders have been the same large-cap, strong-balance sheet stocks that had been outperforming before the outbreak, resulting in a surge in already-elevated market concentration, it said.Goldman’s caution dovetails with that of Bloomberg Intelligence Chief Equity Strategist Gina Martin Adams, who said in a report Thursday that that U.S. equity breadth has not moved at a pace consistent with strong rallies off lows. Less than half the members of the S&P 500 were trading above their 50-day moving average, she noted.In early February, before the coronavirus sell-off, Kostin and his team had downplayed the dominance of large-cap technology giants in the U.S. benchmark, arguing that lower growth expectations, lower valuations and greater reinvestment could help them sustain their leadership.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.




from Yahoo Finance https://ift.tt/2KOpwGx

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be